{
    "clinical_study": {
        "@rank": "47071", 
        "arm_group": [
            {
                "arm_group_label": "Group 1 of Study A", 
                "arm_group_type": "Experimental", 
                "description": "single dosing of Rosuvastatin and Metformin 14 days later, single dosing of YH14755"
            }, 
            {
                "arm_group_label": "Group 2 of Study A", 
                "arm_group_type": "Experimental", 
                "description": "single dosing of YH14755 14 days later, single dosing of Rosuvastatin and Metformin"
            }, 
            {
                "arm_group_label": "Group 1 of Study B", 
                "arm_group_type": "Experimental", 
                "description": "single dosing of YH14755 with fasting state 14 days later, single dosing of YH14755 after having breakfast"
            }, 
            {
                "arm_group_label": "Group 2 of Study B", 
                "arm_group_type": "Experimental", 
                "description": "single dosing of YH14755 after having breakfast 14 days later, single dosing of YH14755 with fasting state"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to Compare the Safety and the Pharmacokinetic Characteristics\n      of the Co-administration of Rosuvastatin and Metformin SR and YH14755 and to Investigate the\n      Effect of Food on the Pharmacokinetics of YH14755 in healthy volunteers."
        }, 
        "brief_title": "Phase 1 Clinical Trial to Investigate the Effect on the Pharmacokinetics of YH14755 Compared to Co-administration of Rosuvastatin and Metformin SR in Healthy Volunteers", 
        "completion_date": {
            "#text": "March 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy male and female with a body mass index(BMI) between 18.5 and 25 kg/m2\n\n          2. Who has not suffered from clinically significant disease\n\n          3. Provision of signed written informed consent\n\n        Exclusion Criteria:\n\n          1. History of and clinically significant disease\n\n          2. A history of drug abuse or the presence of positive reactions to drugs that have\n             abuse potential in urine screenings for drugs.\n\n          3. Administration of other investigational products within 3 months prior to the first\n             dosing.\n\n          4. Administration of herbal medicine within 4 weeks or administration of ethical drugs\n             within 2 weeks or administration of over-the-counter (OTC) drugs within 1 week prior\n             to the first dosing of the investigational product (if the investigator (study\n             doctor) determines that the person meets other criteria appropriately, the relevant\n             person may participate in the study).\n\n          5. Volunteers considered not eligible for the clinical trial by the investigator (study\n             doctor) due to reasons including laboratory test results, ECGs, or vital signs."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "19 Years"
        }, 
        "enrollment": {
            "#text": "56", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02125227", 
            "org_study_id": "YH14755-102"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group 1 of Study A", 
                    "Group 2 of Study A"
                ], 
                "description": "single dose", 
                "intervention_name": "Rosuvastatin, Metformin, YH14755", 
                "intervention_type": "Drug", 
                "other_name": "Crestor, GlucodaunOR, YH14755"
            }, 
            {
                "arm_group_label": [
                    "Group 1 of Study B", 
                    "Group 2 of Study B"
                ], 
                "description": "single dose", 
                "intervention_name": "YH14755", 
                "intervention_type": "Drug", 
                "other_name": "YH14755"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Metformin", 
                "Rosuvastatin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 28, 2014", 
        "number_of_arms": "4", 
        "official_title": "A Randomized, Open-label, Single-dose, 2-Way Cross-over Study to Compare the Safety and the Pharmacokinetic Characteristics of the Co-administration of Rosuvastatin and Metformin SR and YH14755 and to Investigate the Effect of Food on the Pharmacokinetics of YH14755", 
        "overall_contact": {
            "email": "namsu@yuhan.co.kr", 
            "last_name": "Su Youn Nam, MD, Ph.D", 
            "phone": "+82-8-828-0432"
        }, 
        "overall_official": {
            "affiliation": "Chonbuk National University Hospital", 
            "last_name": "min gul kim, MD, Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "AUClast of rosuvastatin and metformin", 
                "safety_issue": "No", 
                "time_frame": "0~48hr, totally 17 points"
            }, 
            {
                "measure": "Cmax of rosuvastatin and metformin", 
                "safety_issue": "No", 
                "time_frame": "0~48hr, totally 17 points"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02125227"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Tmax of rosuvastatin and metformin", 
                "safety_issue": "No", 
                "time_frame": "0~48hr, totally 17 points"
            }, 
            {
                "measure": "t1/2 of rosuvastatin and metformin", 
                "safety_issue": "No", 
                "time_frame": "0~48hr, totally 17 points"
            }, 
            {
                "measure": "%AUC of rosuvastatin and metformin", 
                "safety_issue": "No", 
                "time_frame": "0~48hr, totally 17 points"
            }, 
            {
                "measure": "AUCinf of rosuvastatin and metformin", 
                "safety_issue": "No", 
                "time_frame": "0~48hr, totally 17 points"
            }
        ], 
        "source": "Yuhan Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Yuhan Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}